These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 18349265

  • 21. Targeting prostate cancer bone metastases.
    Logothetis C, Tu SM, Navone N.
    Cancer; 2003 Feb 01; 97(3 Suppl):785-8. PubMed ID: 12548576
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Cancer and bone repair mechanism: clinical applications for hormone refractory prostate cancer.
    Koutsilieris M, Mitsiades C, Lembessis P, Sourla A.
    J Musculoskelet Neuronal Interact; 2000 Sep 01; 1(1):15-7. PubMed ID: 15758519
    [Abstract] [Full Text] [Related]

  • 24. Prostate cancer metastases to bone: pathophysiology, pain management, and the promise of targeted therapy.
    Pinski J, Dorff TB.
    Eur J Cancer; 2005 Apr 01; 41(6):932-40. PubMed ID: 15808959
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. [Mechanism and treatment of cancer metastasis to bone].
    Yoneda T.
    Clin Calcium; 2005 Jul 01; 15(7):29-37. PubMed ID: 15995293
    [Abstract] [Full Text] [Related]

  • 29. Comparison of serum HER2/neu with immunohistochemical HER2/neu expression for the prediction of biochemical progression in metastatic prostate cancer.
    Tambo M, Higashihara E, Terado Y, Nutahara K, Okegawa T.
    Int J Urol; 2009 Apr 01; 16(4):369-74. PubMed ID: 19207111
    [Abstract] [Full Text] [Related]

  • 30. Biochemical markers for monitoring response to therapy: evidence for higher bone specificity by a novel marker compared with routine markers.
    Leeming DJ, Hegele A, Byrjalsen I, Hofmann R, Qvist P, Karsdal MA, Schrader AJ, Wagner R, Olbert P.
    Cancer Epidemiol Biomarkers Prev; 2008 May 01; 17(5):1269-76. PubMed ID: 18483350
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Bone-directed treatments for prostate cancer.
    Saad F.
    Hematol Oncol Clin North Am; 2006 Aug 01; 20(4):947-63. PubMed ID: 16861125
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Bone turnover mediates preferential localization of prostate cancer in the skeleton.
    Schneider A, Kalikin LM, Mattos AC, Keller ET, Allen MJ, Pienta KJ, McCauley LK.
    Endocrinology; 2005 Apr 01; 146(4):1727-36. PubMed ID: 15637291
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Hypocalcemia and parathyroid function in metastatic prostate cancer.
    Tandon PK, Rizvi AA.
    Endocr Pract; 2005 Apr 01; 11(4):254-8. PubMed ID: 16006299
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.